These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 17647172

  • 1. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Miller K, Bergmann L, Albers P, Jäger E, Jakse G, Geschwend JE, Marschner N.
    Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
    [Abstract] [Full Text] [Related]

  • 2. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K, Bergmann L, Jäger E, Jakse G, Wirth M, Keilholz U, interdisziplinäre Arbeitsgruppe Nierenzellkarzinom der Deutschen Krebsgesellschaft e.V. (DKG).
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment options for metastatic renal cell carcinoma: a review.
    Athar U, Gentile TC.
    Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 8. Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
    Di Lorenzo G.
    Eur Urol; 2007 Sep; 52(3):926-8; author reply 928. PubMed ID: 17574728
    [No Abstract] [Full Text] [Related]

  • 9. Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Bamias A.
    Eur Urol; 2009 Jun; 55(6):1439. PubMed ID: 18950935
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Therapy for metastatic RCC--questions remain.
    Breau RH, Leibovich BC.
    Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Pouessel D, Culine S.
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
    Ravaud A, Digue L, Trufflandier N, Smith D.
    Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
    [No Abstract] [Full Text] [Related]

  • 19. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Richards TM, Plowman PN, Reznek R, Ball SA.
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.